Nemaura CY Q4 ‘21 and FY ’21 (FY Q3 ‘22) Earnings Update

Nemaura Medical published its CY Q4 ’21 (FY Q3 ’22) business update (press release), though the company did not host an associated webcast with investors. Of note, the company only provided brief commentary on the launch of MiBoKo (view website) for employer groups and insurers/payers, the MySugarWatch DuoPack Limited deal, and the appointment of Dr. Arash Ghadar (view LinkedIn) as COO. Below are highlights from the press release.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.